Supplementary Materialsbiomolecules-10-00144-s001. CNE1 (nasopharyngeal carcinoma, IC50: 3.66?M), and CNE2 (nasopharyngeal carcinoma, IC50: 5.93?M) cells [25] after 48 h treatment; and EC109 (esophageal carcinoma, IC50: 67.1 M), SHG-44 (glioblastoma, IC50: 53.5 M), MCF-7 (breasts carcinomas, IC50: 72.1 M) [26], and SGC-7901 (gastric carcinoma, IC50: 22.7 M) [27] following 72 h treatment. Kadioglu et al. (2018) examined the cytotoxicity of oridonin in spectral range of drug-resistant tumor AZD5363 cost cell lines including CCRF-CEM (leukemia, IC50: 1.65 M), CEM/ADR5000 (leukemia, AZD5363 cost IC50: 8.53 M), MDA-MB231 (breasts carcinoma, IC50: 6.06 M), MDA-MB231/BCRP (breast carcinoma, IC50: 9.74 M), HCT116 (p53+/+) (IC50: 18.0 M), HCT-116 (p53?/?) (IC50: 34.7 M), U87MG (glioblastoma, IC50: 17.4 M), HepG2 (liver carcinoma, IC50: 25.7 M), and AML12 (liver normal cells, IC50: 109 M) AZD5363 cost cells, but didn’t mention the incubation period with oridonin in these cytotoxic check experiments [28]. Open up in another window Shape 2 Constructions of plant-derived anticancer 0.01) compared to the automobile control group [24]. Gao et al. (2016) reported that oridonin induced apoptosis by downmodulating the manifestation degree of B-cell lymphoma 2 (BCL-2), but upmodulating the manifestation of BAX, reducing the BCL-2/BAX ratio in human gastric cancer SGC-7901 cells thus. Moreover, oridonin treatment activated caspase-3 by promoting the release of cytochrome c from mitochondria to the cytosol [27]. In another study, oridonin potentiated the anticancer activity of lentinan, a polysaccharide isolated from shiitake mushrooms, by upregulating the expression levels AZD5363 cost of caspase-3, -8, -9, BAX, p53, and p21 while downregulating the expression of BCL-2, B-cell lymphoma extra-large (BCL-XL) and epidermal growth factor (EGF) in SMMC-7721 human hepatoma cells [29]. In prostate cancer cells (PC-3 and DU-145), oridonin increased the expression levels of p53, p21, caspase-3, -9, and poly (ADP-ribose) polymerase (PARP), while it decreased cyclin-dependent kinase 1 (CDK1) levels [30]. Moreover, it inhibited the expression of phosphoinositide 3-kinase (PI3K) and blocked phosphorylation of protein kinase B (p-Akt). Sun et al. (2018) reported synergistic anticancer activity of oridonin in combination with lentinan by decreasing the expression of BCL-2 and nuclear factor kappa B (NF-B) and increasing the expression of caspase-3, -9, p53, p21, NF-B inhibitor- (IB-) by increasing transcription of mRNA and translation of the mRNA into their respective protein products in human hepatoblastoma HepG2 cells [31]. In 4T1 human breast cancer cells, oridonin inhibited cellular proliferation, migration, and invasion via a negative modulation of notch1-4. Furthermore, the administration of oridonin (5 mg/kg) significantly ( 0.01) reduced the weight (84%) and volume (72%) of 4T1 tumors compared with the negative control group in a xenograft nude mouse study [32]. 2.2. Eriocalyxin B Eriocalyxin B (C20H24O5, MW: 344.41, Figure 2) was isolated from the plant var. laxiflora [33]. The cytotoxicity of eriocalyxin B was tested in panel of human cell lines such as SMMC-7721 (hepatocarcinoma, IC50: 0.76 M) [33], MCF-7 (IC50: 0.75 M), MDA-MB-231 (IC50: 0.47 M) [34] after 48 h treatment; PANC1 (pancreatic carcinoma, IC50: 1.79 M), CAPAN1 (pancreatic carcinoma, IC50: 0.86 M), CAPAN2 (pancreatic carcinoma, IC50: 0.73 M), SW1990 (pancreatic carcinoma, IC50: 1.40 M), WRL68 (normal human liver cells, IC50: 3.58 M), PBMC (human peripheral blood mononuclear cells, IC50: 5.83 M) [35], SU-DHL-4 (lymphoma, IC50: 1.00 M), Namalwa (lymphoma, IC50: 1.50 M), Raji (lymphoma, IC50: 2.00 M), Jurkat (lymphoma, IC50: 2.00 M), U266 (lymphoma, IC50: 5.60 M) and HUT78 (lymphoma, IC50: 2.50 M) cells [36] after 72 h treatment. The molecular pathways of eriocalyxin B against different cancers have been intensively investigated [33,34,37,38,39]. In hepatocellular carcinoma SMMC-7721 cells, eriocalyxin B induced apoptosis by interfering with the binding of NF-B with the response elements via targeting cysteine 62 moiety of p50 [33]. In a Mouse monoclonal to BID recent study, eriocalyxin B was reported to induce autophagy upon an upregulation of LC3B-II and beclin-1 in MCF-7 and MDA-MB-231 human breast cancer cells; however, the expression of p62 was downregulated. In addition to.